Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 2Glioma 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Histiocytosis, Langerhans-Cell 1Hepatoblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Advanced Malignant Solid Neoplasm 1

Interventions

Rituximab 13Cyclophosphamide 9Magnetic Resonance Spectroscopy 7Lenalidomide 7venetoclax 6obinutuzumab 5ibrutinib 5Specimen Handling 5fludarabine phosphate 4fludarabine 4Whole-Body Irradiation 4Prednisone 4CT-P10 4Biopsy 4zanubrutinib 3orelabrutinib 3Vincristine 3Mycophenolic Acid 3Cyclosporine 3polatuzumab vedotin 2pirtobrutinib 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Doxorubicin 2Busulfan 2Bendamustine Hydrochloride 2voruciclib 1treosulfan 1tafasitamab 1prednylidene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell, Marginal Zone × Pharmacogenomic Variants × 90 days × Clear all
NCT03479268 2026-04-27

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

City of Hope Medical Center

Phase 1 Active not recruiting
18 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡